A Post-hoc Comparison of Paliperidone Palmitate to Oral Risperidone During Initiation of Long-acting Risperidone Injection in Patients with Acute Schizophrenia.

Objective: First-month data of a 13-week acute schizophrenia study were used to compare paliperidone palmitate to oral risperidone during initiation of long-acting injectable risperidone. Design: Double-blind, randomized study. Setting: Outpatient or inpatient. Participants: Adults with established (³1 year) schizophrenia. Those assigned to risperidone longacting injectable (n=460) received 25mg on Days 8 and 22 with oral risperidone (1-6mg) supplementation for the first 28 days. The paliperidone palmitate group (n=453) received 150mg eq. on Day 1, 100mg eq. on Day 8, and oral placebo supplementation for the first 28 days. Measurements: Positive andNegative Syndrome Scale, Personal and Social Performance Scale, Clinical Global Impression-Severity score, and responder rate (percentage of patients with ³30% reduction in PANSS total score). An analysis of covariance model. [ABSTRACT FROM AUTHOR]